Omniscent, a Sydney, Australia-based company using AI to decode the human brain, raised an undisclosed amount in Series C funding.
The round, which brought the total amount to US$60M, saw participation from an undisclosed investor.
Led by CEO Stephen Scheeler, Omniscient (o8t®) uses AI to decode the human brain, a field known as connectomics, and create advanced technologies to enhance the potential of the human brain for the benefit of all humankind. Quicktome, the company’s flagship platform, uses AI to automatically decode and map the brain’s networks—responsible for everything from motor to language to emotion—using just a straightforward MRI scan. Omniscient recently expanded its product offering to include the first FDA-cleared neurological planning and visualization tool using resting-state fMRI, opening up new horizons for Quicktome in areas such as stroke, disorders of consciousness, and oncology.
The company intends to use the funds to expand its presence in the US market – where more than 100 US hospitals and clinics utilize Quicktome – and to advance product development efforts targeting expanded indications.
FinSMEs
11/06/2024